This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Jul 14;353(2):200-2.

doi: 10.1056/NEJMe058113.

Targeting EGFR in non-small-cell lung cancer

James H Doroshow

PMID: 16014890
DOI: 10.1056/NEJMe058113

Editorial

Targeting EGFR in non-small-cell lung cancer

James H Doroshow. N Engl J Med. 2005.

. 2005 Jul 14;353(2):200-2.

doi: 10.1056/NEJMe058113.

Author

James H Doroshow

PMID: 16014890
DOI: 10.1056/NEJMe058113

No abstract available

PubMed Disclaimer

Comment on

Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Shepherd FA, et al. N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753. N Engl J Med. 2005. PMID: 16014882 Clinical Trial.
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Tsao MS, et al. N Engl J Med. 2005 Jul 14;353(2):133-44. doi: 10.1056/NEJMoa050736. N Engl J Med. 2005. PMID: 16014883 Clinical Trial.

Similar articles

Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R, Subramanian J. Govindan R, et al. Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
Erlotinib in lung cancer.
Pao W, Ladanyi M, Miller VA; Lung Cancer Oncogenome Group. Pao W, et al. N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. N Engl J Med. 2005. PMID: 16240471 No abstract available.
Erlotinib in lung cancer.
Takano T, Ohe Y. Takano T, et al. N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. N Engl J Med. 2005. PMID: 16240472 No abstract available.
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K. Nurwidya F, et al. Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Respir Investig. 2014. PMID: 24636263 Review.
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M, Stordal B. Murphy M, et al. Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Drug Resist Updat. 2011. PMID: 21435938 Review.

See all similar articles

Cited by

A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and ¹⁸F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.
Jiang M, Zhang X, Chen Y, Chen P, Guo X, Ma L, Gao Q, Mei W, Zhang J, Zheng J. Jiang M, et al. Front Oncol. 2022 Apr 20;12:780186. doi: 10.3389/fonc.2022.780186. eCollection 2022. Front Oncol. 2022. PMID: 35515138 Free PMC article. Review.
Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice.
Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF. Kim M, et al. Drug Metab Dispos. 2019 Apr;47(4):393-404. doi: 10.1124/dmd.118.084210. Epub 2019 Jan 31. Drug Metab Dispos. 2019. PMID: 30705084 Free PMC article.
EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?
Qin X, Gu X, Lu Y, Zhou W. Qin X, et al. Cancer Manag Res. 2018 Oct 1;10:4019-4027. doi: 10.2147/CMAR.S174623. eCollection 2018. Cancer Manag Res. 2018. PMID: 30323660 Free PMC article.
Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Kim M, et al. Pharm Res. 2018 Jul 12;35(9):177. doi: 10.1007/s11095-018-2455-9. Pharm Res. 2018. PMID: 30003344 Free PMC article. Review.
CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.
Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z. Cheng Z, et al. BMC Med Imaging. 2017 Jan 10;17(1):5. doi: 10.1186/s12880-016-0175-3. BMC Med Imaging. 2017. PMID: 28068946 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal